Takeda Reports Results of Ninlaro (ixazomib) in P-III TOURMALINE-MM2 Study for Transplant Ineligible Patients with Multiple Myeloma

 Takeda Reports Results of Ninlaro (ixazomib) in P-III TOURMALINE-MM2 Study for Transplant Ineligible Patients with Multiple Myeloma

Takeda Reports Results of Ninlaro (ixazomib) in P-III TOURMALINE-MM2 Study for Transplant Ineligible Patients with Multiple Myeloma

Shots:

  • The P-III TOURMALINE-MM2 study involves assessing of Ninlaro + lenalidomide + dexamethasone vs PBO + lenalidomide + dexamethasone in 705 transplant-ineligible patients with newly diagnosed MM
  • The P-III TOURMALINE-MM2 study results: improvement in PFS (35.3 mos. vs 21.8 mos.); safety profile is consistent with the existing prescribing information
  • Ninlaro is an oral proteasome inhibitor, approved in 60+ countries, including the US, EU & Japan with 10+ regulatory filing currently under review. In 2015, the US FDA has approved the triple regimen to treat patients with MM prior treated with at least one therapy

Click here ­to­ read full press release/ article | Ref: Takeda | Image: Twitter

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post